AUX 001
Alternative Names: AUX-001; Nicorandil extended-releaseLatest Information Update: 23 Feb 2024
At a glance
- Originator Auxilius Pharma
- Class Ischaemic heart disorder therapies; Nitrates; Small molecules; Vasodilators
- Mechanism of Action Guanylate cyclase stimulants; KATP channel stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Angina pectoris
Most Recent Events
- 23 Feb 2024 Auxilius Pharma plans to launch AUX 001 for the treatment of Angina pectoris in the US by 2027
- 23 Feb 2024 Auxilius Pharma plans a phase III trial for Angina pectoris in 2025
- 27 Nov 2023 Phase-I clinical trials in Angina pectoris (In volunteers) in Portugal (Parenteral) (NCT06249581) (EudraCT-2023-506085-31-00)